Here's what we'll cover
Here's what we'll cover
Wall Street Is Looking for the Next GLP-1. Some Investors Think It Is Baldness.
The success of GLP-1 medications reshaped the pharmaceutical industry. Weight loss drugs helped push Eli Lilly's market value past $1 trillion and briefly made Novo Nordisk the most valuable company in Europe. Now investors are hunting for the next mass market medicine, and one of the most talked about candidates is a treatment for pattern hair loss, as Fortune reported in August 2026.
For GLP-1 patients, the comparison is more than a market story. It shows what made weight loss drugs different, and it touches a side effect many people on semaglutide or tirzepatide notice firsthand: thinning hair.
Why Investors See Hair Loss as a Huge Market
Pattern hair loss affects an estimated 50 million men and 30 million women in the United States, yet no new drug for it has been approved since the late 1990s, according to Fortune. Today's main options are topical minoxidil, sold over the counter as Rogaine, and prescription finasteride, which some men avoid because of sexual side effects.
That combination of a large population, old treatments, and patients who already pay out of pocket looks attractive to investors who watched GLP-1 demand outrun supply.
The Companies and Drugs Drawing Attention
| Company | Candidate | Status reported in 2026 |
|---|---|---|
| Veradermics | Oral low dose minoxidil tablet | Positive results in male pattern hair loss in April and promising mid stage data in women in July; shares up nearly 500% since its February IPO |
| Cosmo Pharmaceuticals | Clascoterone 5% topical solution | Positive results in men; US new drug application planned for the first quarter of 2027 |
| Absci | ABS-201, an AI designed injection | Early stage; interim data expected in the second half of 2026 |
Jefferies analysts have estimated global sales of about $3 billion for Cosmo's male hair loss therapy, assuming a commercial partner is found. None of these products is approved yet, and Fortune noted that Cosmo's treatment is likely more than a year from US pharmacy shelves.
Hair loss is not entirely new territory for modern drug development. The FDA approved baricitinib (Olumiant) in 2022 as the first systemic treatment for severe alopecia areata, an autoimmune form of hair loss. But alopecia areata is a different condition from common pattern baldness.
Why Hair Loss Drugs Are Unlikely to Repeat the GLP-1 Story
The investment pitch borrows GLP-1 language, but the underlying situations are very different.
GLP-1s Treat a Disease With Measurable Health Outcomes
Obesity and type 2 diabetes drive heart disease, kidney disease, and early death. That is why semaglutide and tirzepatide earned approvals for conditions like cardiovascular risk reduction and sleep apnea, and why insurers and Medicare are slowly expanding coverage. Pattern baldness, by contrast, is not a health crisis, and even supporters expect hair loss drugs to remain cash pay products, as Fortune noted.
Coverage Drove GLP-1 Scale
Even with limited employer coverage for weight loss, GLP-1s reached millions of patients partly through diabetes coverage. A cosmetic indication is unlikely to get that kind of payer support.
The Path Was Not Smooth for Obesity Drugs Either
Before GLP-1s succeeded, many obesity drugs failed commercially, and some companies went bankrupt. Drug Discovery News has pointed out that hair loss developers face similar risks: strong early data does not guarantee approval, safety, or demand.
The Hair Loss Many GLP-1 Patients Already Notice
Hair thinning is a real side effect for some people on GLP-1 medications. In the Wegovy prescribing information, hair loss was reported in about 3% of adults on Wegovy compared with about 1% on placebo. The Zepbound prescribing information reports hair loss in roughly 4% to 5% of patients on tirzepatide compared with about 1% on placebo, with higher rates in women.
In most cases this is thought to be telogen effluvium, a temporary shedding that can follow rapid weight loss, calorie restriction, or other physical stress. It usually appears two to four months after the trigger and often improves as weight stabilizes. It is different from genetic pattern hair loss, although rapid weight loss can make existing thinning more noticeable.
How to Protect Your Hair While on a GLP-1
- Eat enough protein. Many clinicians target about 1.2 to 1.6 grams per kilogram of body weight per day during active weight loss.
- Avoid extreme calorie restriction even when appetite is low. Small, protein focused meals help.
- Ask your doctor to check ferritin, vitamin D, zinc, and thyroid function if shedding is heavy.
- Do not start a new hair loss drug without medical guidance, especially oral minoxidil, which can affect blood pressure and heart rate.
- See a dermatologist if shedding lasts more than six months or you notice patchy hair loss.
Questions to Ask Your Doctor
- Is my hair shedding consistent with telogen effluvium from weight loss?
- Should we slow my dose escalation if I am losing weight very quickly?
- Which lab tests make sense to rule out nutritional or thyroid causes?
- Is it safe for me to use minoxidil or finasteride while on a GLP-1?
- When should I see a dermatologist?
No waiting list. No insurance needed.
Frequently Asked Questions
Why are investors comparing hair loss drugs to GLP-1s?
GLP-1 medications created one of the largest drug markets in history. Investors see pattern hair loss as another huge, underserved market, with about 50 million US men and 30 million US women affected and no new drugs approved since the late 1990s.
Which hair loss drugs are in development in 2026?
Companies drawing attention include Veradermics with an oral minoxidil tablet, Cosmo Pharmaceuticals with clascoterone 5% topical solution, and Absci with an early stage AI designed injection called ABS-201. None is FDA approved for pattern hair loss yet.
Do GLP-1 medications cause hair loss?
Hair loss is a reported side effect. About 3% of Wegovy users reported hair loss versus about 1% on placebo, and roughly 4% to 5% of Zepbound users versus about 1% on placebo. It is usually temporary shedding linked to rapid weight loss.
Is GLP-1 hair loss permanent?
Usually not. Most cases are telogen effluvium, a temporary shedding that begins two to four months after rapid weight loss and often improves as weight stabilizes. Persistent or patchy hair loss should be evaluated by a dermatologist.
How can I reduce hair loss while taking semaglutide or tirzepatide?
Eat adequate protein, avoid extreme calorie restriction, and ask your doctor about checking ferritin, vitamin D, zinc, and thyroid levels. A slower pace of weight loss may also help.
Can I take minoxidil or finasteride with a GLP-1?
Many people can, but discuss it with your doctor first. Oral minoxidil can lower blood pressure and raise heart rate, which matters if you are losing weight quickly or taking blood pressure medicines.
The Bottom Line
Investors are betting that hair loss could be the next big consumer medicine after GLP-1s, with companies like Veradermics, Cosmo, and Absci drawing attention in 2026. But the comparison has limits. GLP-1s treat chronic diseases with proven health benefits and growing insurance coverage, while pattern baldness treatments are likely to remain cash pay.
If you are on Wegovy, Ozempic, or Mounjaro and notice shedding, it is usually temporary and manageable with adequate protein, a gradual pace of weight loss, and a check of nutritional labs. To find a prescriber who monitors side effects like hair loss, compare vetted telehealth providers, and review current GLP-1 coupons and savings programs. Always consult your physician before adding any new medication.